Whalesbook
📉 The Financial Deep Dive
Aarti Drugs Limited's Q3 FY26 performance presented a mixed picture, with strong profit growth overshadowed by margin compression and operational headwinds. Consolidated revenue climbed 8% year-on-year (YoY) to INR602.9 crores from INR557.1 crores in the prior year period. Despite this top-line expansion, EBITDA saw a 10% YoY decline, settling at INR56.3 crores compared to INR62.3 crores. This resulted in a significant contraction of the EBITDA margin to 9.3% from levels seen in the previous year.
However, Profit After Tax (PAT) demonstrated remarkable resilience, surging 58% YoY to INR40.5 crores from INR25.7 crores. This substantial PAT growth, leading to a 6.7% PAT margin, was likely influenced by factors such as improved cost efficiencies, potential tax benefits, or a lower base in the prior year, as detailed by management.
For the nine-month period (9M FY26), consolidated revenue increased by 8% YoY to INR1,846.6 crores. EBITDA grew 9% YoY to INR215.0 crores, maintaining a margin of 11.6%, while PAT rose by a substantial 49% YoY to INR139.7 crores, reflecting a 7.6% margin for the period.
❓ The Grill & Management Commentary
Management attributed the Q3 performance challenges to several factors. These included low plant utilization levels, a weaker demand environment for antibiotics, and shipment delays originating from China. A one-time voluntary plant shutdown for refurbishment and the operation of new greenfield facilities (like Sayakha) below optimal capacity also impacted results. Collectively, these headwinds are estimated to have caused an EBITDA drag of INR8-8.5 crores and a Profit Before Tax (PBT) drag of INR14-15 crores for the quarter. Furthermore, the strategy of selling existing stock reportedly affected gross margins by approximately 1%.
On a brighter note, the standalone business achieved 7% volume growth YoY. Exports, particularly in the formulations segment, emerged as a significant growth driver. The formulations business itself saw a strong 58% YoY increase to INR76.6 crores in Q3 FY26, with exports constituting 67% of this segment. The new Sayakha facility, commissioned in September 2025, reached 30% utilization in its inaugural quarter and aims for 50% by March/April 2026. The company is actively pursuing its backward integration strategy, especially for antidiabetic intermediates, targeting full self-reliance. Production at the salicylic acid facility is scaling up to over 300 tons per month.
🚩 Risks & Outlook
Looking ahead, Aarti Drugs anticipates a turn in performance. The company projects 12-15% volume growth for FY27, buoyed by the ramp-up of new facilities including Salicylic Acid and Sayakha methyl amine. Management's target is to achieve steady-state EBITDA margins of 14-15% and a 36% gross margin for standalone API in FY27. The company plans a consistent capital expenditure of INR150-200 crores annually over the next two years, focusing on capacity expansions, new product development (including oncology), enhancing CDMO capabilities, and energy efficiency improvements. The consolidated debt stands at approximately INR540 crores, a figure that investors will monitor in conjunction with the planned CapEx.
The key risks for investors to watch include the pace of recovery in antibiotic demand, successful ramp-up of new facilities to optimal capacity, execution of the backward integration plans, and competitive pricing pressures in the API market.